BLUEROCK
Live / Applied — Fourth extension granted (statement of use) (as of 04 Nov 2025)
What this means for you
Not registered yet, but its 13 Jul 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97501359
- Mark type
- Stylized text
- Filed
- 13 Jul 2022
- Published for opposition
- 19 Sept 2023
- Attorney of record
- Phillip Barengolts
Goods and services
- Class 005 — Pharmaceuticals: Cells for medical or clinical use; genetic material being cells and biological tissue cultures for medical or clinical use; cell therapy and genetic medicine-based pharmaceutical and therapeutic pharmaceutical preparations for the treatment of Parkinson's disease, cancer, cardiovascular disease, ophthalmological diseases, autoimmune disorders, neurological disorders, lysosomal disorders, central nervous system diseases, gastrointestinal disorders, dermatological disorders, inflammatory diseases, metabolic disorders, respiratory diseases, and endocrine diseases; pharmaceutical and therapeutic pharmaceutical preparations in the nature of cells for human use for treating Parkinson's disease, cancer, cardiovascular disease, ophthalmological diseases, autoimmune disorders, neurological disorders, lysosomal disorders, central nervous system diseases, gastrointestinal disorders, dermatological disorders, inflammatory diseases, metabolic disorders, respiratory diseases, and endocrine diseases through cell therapy or gene therapy; cell therapy and genetic medicine-based pharmaceutical preparations for the treatment of Parkinson's disease, cancer, cardiovascular disease, ophthalmological diseases, autoimmune disorders, neurological disorders, lysosomal disorders, central nervous system diseases, gastrointestinal disorders, dermatological disorders, inflammatory diseases, metabolic disorders, respiratory diseases, and endocrine diseases through gene therapy and cell therapy
- Class 042 — Scientific and technological services: Medical and scientific research services in the fields of gene therapy and cell therapy; pharmaceutical research and development services
- Class 044 — Medical, beauty and agricultural services: Medical treatment of Parkinson's disease, cancer, cardiovascular disease, ophthalmological diseases, autoimmune disorders, neurological disorders, lysosomal disorders, central nervous system diseases, gastrointestinal disorders, dermatological disorders, inflammatory diseases, metabolic disorders, respiratory diseases, and endocrine diseases; collection and preservation of human biological tissue, blood and cells for medical diagnostic testing purposes; medical diagnostic testing, monitoring and reporting services
Owner
- BlueRock Therapeutics LP, Cambridge, MA, US
- BlueRock Therapeutics LP, Cambridge, MA, US
Prior registrations
Prosecution history
- 05 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Nov 2025 — SOU EXTENSION 4 GRANTED
- 04 Nov 2025 — SOU EXTENSION 4 FILED
- 04 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 06 May 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 06 May 2025 — SOU EXTENSION 3 GRANTED
- 05 May 2025 — SOU EXTENSION 3 FILED
- 05 May 2025 — SOU TEAS EXTENSION RECEIVED
- 17 Dec 2024 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 17 Dec 2024 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 17 Dec 2024 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 24 Oct 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Oct 2024 — SOU EXTENSION 2 GRANTED
- 24 Oct 2024 — SOU EXTENSION 2 FILED
- 24 Oct 2024 — SOU TEAS EXTENSION RECEIVED